INTRODUCTION
Surgical resection is viewed as the gold standard of treatment for resectable liver metastasis from colorectal cancer (CRLM) [1, 2] . Several groups have reported 5-year survival rates in the range of 23 to 71% for surgical resection [3, 4] . However, only 10 to 20% of patients with CRLM are candidates for surgical resection; the majority are not suitable for resection because of anatomically ill-located lesions, functional insufficiency of hepatic reserves, medical comorbidities and extra-hepatic metastasis [5] . Radiofrequency ablation (RFA) is an alternative therapy for CRLM when hepatic resection cannot be performed. RFA has the advantage of being minimally invasive and is a relatively low-risk procedure for the treatment of focal liver tumors, especially in comparison with open surgical resection [6] . On the other hand, RFA carries its own associated morbidity and mortality rates in both immediate post-procedure and over the long term [7] .
Furthermore, there are unresolved technical limitations thesurgery.or.kr associated with RFA, such as heat sink effects on nearby blood vessels and local tissue destruction [8] . Local recurrence remains one of the greatest disadvantages of RFA for the treatment of hepatic tumors [9] . There are conflicting reports in the literature on the comparative efficacy of RFA and hepatic resection. Some results support a prospective clinical trial comparing RFA and resection, while other reports indicate that RFA is inferior to surgical resection [4, 10, 11] . Although surgery is still the recommended treatment modality for patients with CRLM, the majority of these patients are not surgical candidates [12] .
There are few reports in the literature of randomized controlled trials comparing RFA and resection for CRLM, and analysis of comparative outcomes between RFA and resection has yielded somewhat inconsistent results. Thus, the exact role and long-term outcomes associated with RFA for CRLM are unclear. The purpose of the current study was to evaluate the comparative therapeutic efficacy of RFA and hepatic resection for CRLM.
METHODS

Eligibility and enrollment
Between January 1996 and August 2008, 505 patients with CRLM underwent RFA, hepatic resection or a combination of RFA and resection at Asan Medical Center. All patients had liver metastasis with diagnoses by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasonography or biopsy. Patients with extrahepatic metastasis were excluded when treatment of CRLM was performed. Of the 301 patients who underwent hepatic resection, 23 patients with positive resection margin were also excluded. Of the 482 patients included in the study, 177 were treated by RFA, 278 by curative surgical resection, and 27 by combination therapy. Synchronous colorectal cancer and liver metastases were identified in 258 (53.5%) patients and metachronous liver metastases were detected in 224 (46.5%) of the 482 patients. RFA was performed in cases of surgery-prohibitive comorbidities such as severe cardiovascular or pulmonary disease, difficult anatomical site for surgical resection, and more than four hepatic metastases over the entire liver [13, 14] . A total of 44 (24.9%) of the 177 patients presented with comorbid diseases (13 cases of chronic obstructive pulmonary disease, 4 cases of chronic renal failure, 10 cases of liver cirrhosis, 2 transplantations and 15 cases of heart failure), and the position of the hepatic lesion was located in an anatomic site difficult for resection, such as the center of the liver, in 38 (21.5%) of the 177 patients. Otherwise, all patients with CRLM were initially considered for resection. All patients were recruited prospectively. The endpoints were recurrence, disease-free survival (DFS) and overall survival Values are presented as mean ± SD or number (%). RFA, radiofrequency ablation. 
Statistical analysis
RESULTS
Clinical characteristics of the patients
The clinical characteristics of the 482 patients included in the analysis are summarized in Table 1 (RFA, 177 pa-thesurgery.or.kr tients; resection, 278 patients; combination therapy, 27 patients). Examples of radiologic findings indicating that RFA was recommended in the current study are presented in Fig. 1 Values are presented as mean ± SD or number (%). CRLM, colorectal liver metastasis; RFA, radiofrequency ablation. Table 2 and solitary CRLM ≥ 3 cm in Table 3 .
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Factors associated with OS and DFS
Univariate and multivariate analysis using Cox proportional hazard analysis revealed several factors associated with OS after treatment of liver metastasis (Table 4) . OS correlated with age (P = 0.002), number of liver metastases (P ＜ 0.001) and use of chemotherapy (P = 0.002). Factors associated with DFS after treatment of liver metastasis were also analyzed ( Table 5 ). DFS was significantly related to type of treatment (RFA, P = 0.004) and number of liver metastases (P ＜ 0.001).
Outcome for patients according to patterns of liver metastases
Of the 482 patients, 296 (61.4%) had solitary liver metastasis. In the 226 patients with a single metastatic tumor ＜3 cm (99 patients in the RFA group, 127 patients in the resection group), OS and DFS rates did not differ between patients who underwent RFA and resection (P = 0.96 and 0.98, respectively). Specifically, 5-year OS and DFS rates were 51.1% and 33.6%, respectively, in the RFA group and 51.2% and 31.6%, respectively, in the resection group (Fig. 2) . Among the 70 patients with solitary metastatic tumor ≥3 cm (14 patients in the RFA group and 56 patients in the resection group), DFS rates were significantly lower in the RFA group (RFA group, 23.1%; resection group, 36.6%; P = 0.01) (Fig. 3) .
OS and DFS rates of the 186 patients with multiple liver metastases are shown in Fig. 4 (RFA, 64 patients; resection, 95 patients; combination therapy, 27 patients). There were no statistically significant differences in OS rates among the groups (P = 0.330). Five-year OS was 14.3% in the RFA group, 34.6% in the resection group, and 22.9% in the combination therapy group. However, DFS in the RFA group was significantly lower than the other groups (P = 0.037).
The 5-year DFS rate was 6.4% in the RFA group, 16.2% in the resection group, and 18.4% in the combination therapy thesurgery.or.kr group.
Of the 224 patients with metachronous liver metastases, 148 had solitary liver metastasis (RFA group, 103 patients; resection group, 45 patients). The 5-year OS rate was 47.6%
in the RFA group and 56.0% in the resection group (P = 0.308). There was no statistical difference in 5-year DFS between the RFA and the resection groups (32.2% vs. 34.0%, P = 0.164). A trend in OS and DFS rates was observed, but the difference was not statistically significant.
DISCUSSION
RFA produces coagulation necrosis using a high-frequency alternating current delivered through an electrode placed in the center of the tumor [8] . RFA treatment often results in local tissue temperatures that approach or exceed 100 o C, inducing parenchyma and tumor cell death.
Ultimately, the local microvasculature is destroyed as a result of thrombosis. The use of RFA is generally not recommended for tumors larger than 5 to 6 cm because of technical limitations and the inability to achieve complete necrosis [15] . The purpose of the current study was to com- RFA has been shown to be much less invasive than hepatic resection, with a lower complication rate and shorter hospital stays [3, [16] [17] [18] . Our results were consistent with these studies. Results from a large multicenter study demonstrated that RFA is a relatively safe procedure for treating focal liver tumors, with a very low mortality rate of 0.2% and a major complication rate of 2.2% [6] . Although RFA has been investigated as an alternative to surgery in terms of safety and feasibility, the comparative effective- [20] . The results of the present study are consistent with these earlier studies as well as previous work by our group showing that RFA is a viable alternative treatment for solitary CRLM smaller than 3 cm [11] . On the other hand, several studies have shown that RFA is associated with higher local recurrence and shorter time to progression, and that there is no difference in OS compared to hepatic resection for CRLM [10, 21] . These results are in line with the current finding that there was no statistically significant difference in OS between RFA and resection.
RFA and resection were equivalent in terms of survival outcome in patients with solitary liver metastasis of less than 3 cm. Several studies support hepatic resection as the preferred treatment for CRLM, even in patients with solitary tumors of less than 3 cm [3, 11, 22, 23] . It has also been reported that survival following RFA for patients with unresectable tumors is only slightly superior to nonsurgical treatment [24] . In the current study, the survival rate of the hepatic resection group was higher than the RFA group in patients with solitary CRLM ≥3 cm. For patients with solitary CRLM smaller than 3 cm, our results suggest that RFA is equivalent to hepatic resection. These findings appear to contradict the results of earlier studies, including previous work by our group looking at a smaller number of patients [11] . However, these discrepancies may be due to improvements in the technical accuracy and performance of RFA in accordance with learning curve. in agreement with previous reports that using RFA in addition to resection is beneficial in patients with multiple liver metastases because of the ability to extend the limits of resection [26, 27] .
Multivariate analysis identified the number of liver metastases and treatment with chemotherapy as risk factors for OS and the number of liver metastases and type of treatment as risk factors for DFS. These results suggest that systemic treatment may be more important for OS [28] , and that local controls might be more important for DFS. The synchronicity of liver metastasis may also be an important factor in deciding whether to perform RFA or resection. In patients with metachronous CRLM, there is a tendency to avoid operation if possible because of invasiveness. Likewise, risk of damage to the diaphragm, adjacent stomach or colon would be factors against the use of RFA. For patients with solitary metachronous CRLM who want to avoid hepatic resection, RFA appears to be an attractive alternative. RFA technology continues to improve, and it may soon be possible to achieve precise targeting of tumors and larger ablation zones with a single electrode position [29] . Thus, RFA has the potential to improve survival rates and reduce complications in selected patients with CRLM who are not suitable for or refuse hepatic resection because of comorbidities. The limitation of the present study was that this report was based on not a randomized controlled study, but a retrospective study.
In conclusion, the present study suggests that RFA may be a safe alternative tool for the treatment of solitary CRLM less than 3 cm, with outcomes equivalent to those achieved with hepatic resection. A prospectively controlled study of RFA and resection for patients with single small metastasis would help to determine the most efficient treatment modalities for CRLM.
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